Timber Pharmaceuticals Announces FDA Grant Of CARC Waiver For TMB-001
Portfolio Pulse from Benzinga Newsdesk
Timber Pharmaceuticals announced that the FDA has granted a Competitive Application Review Cycle (CARC) waiver for TMB-001, a topical treatment for ichthyosis. This waiver will expedite the review process for TMB-001.
June 05, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Timber Pharmaceuticals' stock may see a positive impact as the FDA granted a CARC waiver for TMB-001, expediting the review process.
The FDA granting a CARC waiver for TMB-001 is a positive development for Timber Pharmaceuticals. This waiver will expedite the review process, potentially bringing the product to market sooner. As a result, TMBR's stock price may see a positive short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100